Data obtained in vitro were validated ex vivo in PBMCs of MS patients treated with cladribine for the genes NHLRC2 and PPIF, and for the miRNAs miR-30e-5p, miR-21-5p, and miR-30b-5p. This evidence concerns the gene NHLRC2 and myeloid sarcoma.